We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial

News   Oct 20, 2016

 
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial
 
 
Advertisement
 

RELATED ARTICLES

Only Around 60% of Recovered COVID-19 Patients Develop Protective Antibodies

News

Scientists have found that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies. They also showed that some antibodies even "assist" the virus in infecting host cells.

READ MORE

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

RLF-100 Trial Shows Rapid Recovery From Respiratory Failure in Critically Ill Patients With COVID-19

News

A clinical trial of RLF-100 (aviptadil) has shown rapid recovery from respiratory failure in critically ill patients with COVID-19.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE